Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum heme, specifically ferriprotoporphyrin IX (FP-IX), is a toxic byproduct generated during the intraerythrocytic stage of the malaria parasite's life cycle (Egan, 2008). As the parasite digests host hemoglobin to obtain essential amino acids, it releases large quantities of free heme, which can cause oxidative damage to parasite membranes and enzymes (Sullivan, 2002). To survive, the parasite detoxifies this heme by sequestering it into an insoluble crystalline form known as hemozoin, or malaria pigment, within its acidic food vacuole (Egan, 2008). This detoxification process is a critical vulnerability and serves as the primary target for several classes of antimalarial drugs. Quinoline-based drugs, such as chloroquine and quinine, act by binding to heme and preventing its incorporation into hemozoin, leading to the accumulation of toxic heme-drug complexes that kill the parasite (Sullivan, 2002). Additionally, artemisinin-based compounds are activated by the ferrous iron (Fe2+) within heme or the labile iron pool to generate reactive oxygen species and carbon-centered radicals that alkylate parasite proteins (Klonis et al., 2011). Consequently, targeting heme metabolism and its interaction with iron remains a cornerstone of malaria chemotherapy, although the emergence of resistant strains poses a significant challenge to global health efforts (Tilley et al., 2016).
Inhibition of hemozoin formation; Generation of reactive oxygen species via iron-mediated activation; Formation of toxic heme-drug complexes
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum heme (ferriprotoporphyrin IX) (FP-IX).